REFERENCES
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
- Granich R, Crowley S, Vitoria M, et al. Highly active anti-retroviral treatment for the prevention of HIV transmission. J Int AIDS Soc. 2010;13(1):1.
- Lima VD, Hogg RS, Montaner JS. Expanding HAART treat-ment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One. 2010;5(6):e10991.
- EACS Guidelines V. 5–4. http://www.europea-naidsclinicalsociety.org/index.php?option=com_content&view=article&id=59:eacs-guidelines&catid=37:guidelines&Itemid=41. Accessed September 12, 2011.
- Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA. 2010;304(3):321–333.
- Pugliese P, Cuzin L, Cabie A, et al. A large French prospec-tive cohort of HIV-infected patients: the Nadis Cohort. HIV Med. 2009;10(8):504–511.
- Late diagnosis in the HAART era: proposed com-mon definitions and associations with mortality. AIDS. 2010;24(5):723–727.
- Jaen A, Esteve A, Miro JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008;47(2):212–220.
- Agence Nationale de Recherche sur le Sida et les hépatites virales. Rapport d'activité. http://www.anrs.fr/Qui-som-mes-nous/Actualites/Le-rapport-d-activite-2010-de-I-ANRS-est-paru. Accessed September, 12, 2011.
- Cazein F, Lot F, Pillonel F, et al. Surveillance of HIV/AIDS infection in France, 2009. Bulletin Epidemiologique Heb-domadaire. 2010(45–46):467-472.
- Delpierre C, Cuzin L, Lert F. Routine testing to reduce late HIV diagnosis in France. BMJ. 2007;334(7608): 1354–1356.
- Yazdanpanah Y, Sloan CE, Charlois-Ou C, et al. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 2010;5(10):e13132.